Nilo B. Cater

2.3k total citations
35 papers, 1.6k citations indexed

About

Nilo B. Cater is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Nilo B. Cater has authored 35 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in Nilo B. Cater's work include Diabetes Treatment and Management (14 papers), Lipoproteins and Cardiovascular Health (11 papers) and Metabolism, Diabetes, and Cancer (7 papers). Nilo B. Cater is often cited by papers focused on Diabetes Treatment and Management (14 papers), Lipoproteins and Cardiovascular Health (11 papers) and Metabolism, Diabetes, and Cancer (7 papers). Nilo B. Cater collaborates with scholars based in United States, Sweden and Canada. Nilo B. Cater's co-authors include Scott M. Grundy, Gloria Lena Vega, John J.P. Kastelein, Ingar Holme, Anders Olsson, Terje R. Pedersen, Margo A. Denke, Michael Szarek, Ana-Bárbara García-García and Steven N. Blair and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and American Journal of Clinical Nutrition.

In The Last Decade

Nilo B. Cater

35 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nilo B. Cater United States	18	846	736	431	251	152	35	1.6k
Giovanni Battista Vigna Italy	21	806 1.0×	479 0.7×	397 0.9×	202 0.8×	266 1.8×	55	1.5k
Matilda Florentin Greece	24	719 0.8×	584 0.8×	274 0.6×	255 1.0×	161 1.1×	73	1.7k
Antonio J. Vallejo‐Vaz Spain	19	877 1.0×	469 0.6×	369 0.9×	123 0.5×	282 1.9×	51	1.5k
Masumi Ai Japan	24	850 1.0×	962 1.3×	386 0.9×	289 1.2×	296 1.9×	68	1.8k
Thomas Littlejohn United States	22	392 0.5×	601 0.8×	607 1.4×	222 0.9×	75 0.5×	43	1.4k
Helmut Schulte Germany	7	795 0.9×	817 1.1×	370 0.9×	145 0.6×	248 1.6×	7	1.4k
Joel Neutel United States	20	518 0.6×	554 0.8×	1.1k 2.6×	215 0.9×	78 0.5×	48	1.9k
Sephy Philip United States	18	569 0.7×	557 0.8×	367 0.9×	120 0.5×	96 0.6×	57	1.1k
Tu T. Nguyen United States	18	733 0.9×	492 0.7×	196 0.5×	207 0.8×	158 1.0×	30	1.3k
Irene F. Gazi Greece	21	711 0.8×	668 0.9×	180 0.4×	301 1.2×	289 1.9×	35	1.6k

Countries citing papers authored by Nilo B. Cater

Since Specialization

Citations

This map shows the geographic impact of Nilo B. Cater's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nilo B. Cater with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nilo B. Cater more than expected).

Fields of papers citing papers by Nilo B. Cater

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nilo B. Cater. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nilo B. Cater. The network helps show where Nilo B. Cater may publish in the future.

Co-authorship network of co-authors of Nilo B. Cater

This figure shows the co-authorship network connecting the top 25 collaborators of Nilo B. Cater. A scholar is included among the top collaborators of Nilo B. Cater based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nilo B. Cater. Nilo B. Cater is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pandey, Ambarish, Ahmed A. Kolkailah, Robert Frederich, et al.. (2025). Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial. European Journal of Heart Failure. 27(3). 521–526. 1 indexed citations

Sridhar, Vikas S., Francesco Cosentino, Samuel Dagogo‐Jack, et al.. (2024). Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV. Diabetes Obesity and Metabolism. 26(11). 5336–5346. 3 indexed citations

Cosentino, Francesco, Samuel Dagogo‐Jack, Robert Frederich, et al.. (2024). Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial. Diabetes Obesity and Metabolism. 27(2). 583–594. 2 indexed citations

Ji, Linong, Jie Liu, Zhi Jin Xu, et al.. (2023). Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity. Diabetes Therapy. 14(2). 319–334. 1 indexed citations

Inzucchi, Silvio E., Ian J. Neeland, James P. Mancuso, et al.. (2022). Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing. 27(2). 669–672. 27 indexed citations

Cosentino, Francesco, Christopher P. Cannon, David Z.I. Cherney, et al.. (2020). Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation. 142(23). 2205–2215. 175 indexed citations

McNeill, Ann, Glenn Davies, Eliza Kruger, et al.. (2019). Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. Diabetes Therapy. 10(2). 473–491. 20 indexed citations

Ezekowitz, Michael D., Charles V. Pollack, Paul W. Sanders, et al.. (2016). Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. American Heart Journal. 179. 59–68. 24 indexed citations

Pedersen, Terje R., Nilo B. Cater, Ole Færgeman, et al.. (2010). Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial). The American Journal of Cardiology. 106(3). 354–359. 28 indexed citations

10.

Tikkanen, Matti J., Michael Szarek, Rana Fayyad, et al.. (2009). Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy. Journal of the American College of Cardiology. 54(25). 2353–2357. 44 indexed citations

11.

Tikkanen, Matti J., Ingar Holme, Nilo B. Cater, et al.. (2009). Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study). The American Journal of Cardiology. 103(5). 577–582. 46 indexed citations

12.

Holme, Ingar, Nilo B. Cater, Ole Færgeman, et al.. (2008). Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine. 40(6). 456–464. 44 indexed citations

13.

Kastelein, John J.P., Wim A. van der Steeg, Ingar Holme, et al.. (2008). Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation. 117(23). 3002–3009. 376 indexed citations

14.

Kastelein, John J.P., Ingar Holme, Philip J. Barter, et al.. (2006). Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials. Circulation. 114. 2 indexed citations

15.

Cater, Nilo B., Ana-Bárbara García-García, Gloria Lena Vega, & Scott M. Grundy. (2005). Responsiveness of Plasma Lipids and Lipoproteins to Plant Stanol Esters. The American Journal of Cardiology. 96(1). 23–28. 49 indexed citations

16.

Vega, Gloria Lena, et al.. (2005). Influence of Extended-Release Nicotinic Acid on Nonesterified Fatty Acid Flux in the Metabolic Syndrome With Atherogenic Dyslipidemia. The American Journal of Cardiology. 95(11). 1309–1313. 64 indexed citations

17.

Vega, Gloria Lena, Nilo B. Cater, Neil Filipchuk, et al.. (2003). Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. The American Journal of Cardiology. 91(8). 956–960. 125 indexed citations

18.

Cater, Nilo B. & Abhimanyu Garg. (2002). The effect of dietary intervention on serum lipid levels in type 2 diabetes mellitus. Current Diabetes Reports. 2(3). 289–294. 4 indexed citations

19.

Blair, Steven N., David M. Capuzzi, Sidney O. Gottlieb, et al.. (2000). Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. The American Journal of Cardiology. 86(1). 46–52. 169 indexed citations

20.

Cater, Nilo B.. (2000). Plant Stanol Ester: Review of Cholesterol‐Lowering Efficacy and Implications for Coronary Heart Disease Risk Reduction. Preventive Cardiology. 3(3). 121–130. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact